Drug Trial Radar · NCT02558400
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
718
Actual
Start
Sep 18, 2015
Primary completion
May 17, 2017
Study completion Jun 30, 2017
Sponsor
- Lead sponsor
- Aerie PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution. Following completion of the Month 12 study visit procedures, subjects will be offered the opportunity to participate in a 2-month observational (i.e., non-interventional) trial extension.
Conditions
- Open-angle Glaucoma
- Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%Drug
1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%Drug
1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Latanoprost Ophthalmic Solution 0.005%Drug
1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP)Time frame: Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aerie Pharmaceuticals
Bedminster, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.